Last reviewed · How we verify

Cabotegravir Injectable Suspension — Competitive Intelligence Brief

Cabotegravir Injectable Suspension (Cabotegravir Injectable Suspension) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Integrase strand transfer inhibitor (INSTI). Area: Infectious Disease.

marketed Integrase strand transfer inhibitor (INSTI) HIV integrase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Cabotegravir Injectable Suspension (Cabotegravir Injectable Suspension) — ViiV Healthcare. Cabotegravir is an integrase strand transfer inhibitor that blocks HIV integrase, preventing the virus from inserting its genetic material into human DNA.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Cabotegravir Injectable Suspension TARGET Cabotegravir Injectable Suspension ViiV Healthcare marketed Integrase strand transfer inhibitor (INSTI) HIV integrase
Bictegravir, emtricitabine, and tenofovir alafenamide Bictegravir, emtricitabine, and tenofovir alafenamide CAN Community Health marketed Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitors) HIV integrase, HIV reverse transcriptase
Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir St Stephens Aids Trust marketed Antiretroviral agents (INSTI, NNRTI, NRTI/NtRTI) HIV integrase (dolutegravir); HIV reverse transcriptase (efavirenz and combination); HIV entry (tenofovir/emtricitabine component)
GI265235 GI265235 ViiV Healthcare marketed HIV integrase strand transfer inhibitor (INSTI) HIV integrase
Eviplera® Eviplera® St Stephens Aids Trust marketed Antiretroviral combination therapy (NNRTI + NRTI + NtRTI) HIV reverse transcriptase, HIV integrase
DTG/ABC/3TC DTG/ABC/3TC Harvard School of Public Health (HSPH) marketed Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors) HIV integrase, HIV reverse transcriptase
Nevirapine, FTC, and Tenofovir Nevirapine, FTC, and Tenofovir University of Maryland, Baltimore marketed Antiretroviral combination (NNRTI + NRTI + NtRI) HIV reverse transcriptase, HIV integrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Integrase strand transfer inhibitor (INSTI) class)

  1. ViiV Healthcare · 12 drugs in this class
  2. National Institute of Allergy and Infectious Diseases (NIAID) · 5 drugs in this class
  3. Merck Sharp & Dohme LLC · 5 drugs in this class
  4. Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · 1 drug in this class
  5. Germans Trias i Pujol Hospital · 1 drug in this class
  6. Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux · 1 drug in this class
  7. ANRS, Emerging Infectious Diseases · 1 drug in this class
  8. Massachusetts General Hospital · 1 drug in this class
  9. University of Colorado, Denver · 1 drug in this class
  10. MU-JHU CARE · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cabotegravir Injectable Suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/cabotegravir-injectable-suspension. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: